Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMass General Brigham Entyvio SC Coverage | OpenPay…
    Ask Trek AI about this page
    ModifiedMass General Brigham Health PlanPolicy N/A

    Entyvio SC (vedolizumab) Coverage Criteria

    Customize your policy alerts

    Sign up for all Mass General Brigham Health Plan policy alerts

    Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and pharmacy coverage for Entyvio SC in adults with moderately to severely active ulcerative colitis or Crohn's disease under the commercial/Exchange pharmacy benefit.

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyEntyvio SC (vedolizumab) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJanuary 1, 2027
    Last ReviewOct 14, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of the applicable diagnosis and either at least two Entyvio IV doses or trial, failure, contraindication, or intolerance to two listed alternatives.
    SourceLink
    POLICY UPDATE CHANGES

    Xeljanz/tofacitinib was removed as a previous trial option.

    Preferred adalimumab products were updated throughout the policy.

    24 monthsApproval duration
    2 pens/28 daysQuantity limit
    2 dosesRequired IV exposure
    2 therapies

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Alternatives required
    Improvement requiredReauthorization response

    Coverage Criteria

    New-to-plan current treatment

    Authorization may be granted when the member is new to the plan and current treatment with the requested drug is documented.

    New-to-plan current treatment: Member's coverage effective date is less than or equal to 90 days and medical records document that the member is currently receiving treatment with the requested drug.Coverage effective date <= 90 days

    Treatment obtained as samples or through a manufacturer's patient assistance program does not satisfy this pathway.

    Moderately to severely active ulcerative colitis

    Authorization may be granted when all of the following are met:

    Ulcerative colitis criteria

    • Treatment pathway

      • Entyvio IV induction pathway: Entyvio subcutaneous formulation will be used as maintenance following at least two doses of Entyvio IV induction.At least 2 Entyvio IV doses
      • Entyvio IV continuation pathway: Member started therapy with at least two doses of Entyvio IV and is continuing treatment with the subcutaneous formulation.At least 2 Entyvio IV doses
      • Alternative therapy history

        • Adalimumab-aaty, adalimumab-adaz, or Hadlima
        • Omvoh
        • Rinvoq
        • Simponi
        • Skyrizi
        • Selarsdi, Steqeyma, or Yesintek
        • Tremfya

    Moderately to severely active Crohn's disease

    Authorization may be granted when all of the following are met:

    Crohn's disease criteria

    • Treatment pathway

      • Entyvio IV induction pathway: Entyvio subcutaneous formulation will be used as maintenance following at least two doses of Entyvio IV induction.At least 2 Entyvio IV doses
      • Entyvio IV continuation pathway: Member started therapy with at least two doses of Entyvio IV and is continuing treatment with the subcutaneous formulation.At least 2 Entyvio IV doses
      • Alternative therapy history

    Continuation of therapy

    Requests for reauthorization will be approved when all of the following criteria are met:

    Clinical response: Medical records, such as chart notes, document an improvement in the member's condition, evidenced by low disease activity or improvement in signs and symptoms of the condition.Low disease activity or improvement in signs and symptoms

    Provider Actions and Authorization Requirements

    Prior Authorization

    Prior Authorization and Specialty Pharmacy Required

    Prior authorization is required for Entyvio SC. Entyvio SC is covered under the pharmacy benefit and must be filled through a contracted specialty pharmacy.

    • Specialty pharmacy contact: 833-895-2611; Fax: 888-656-6671.
    Prior Authorization

    Initial Authorization Criteria

    Initial authorization may be granted through either the new-to-plan current-treatment pathway or an applicable diagnosis-specific pathway for moderately to severely active ulcerative colitis or Crohn's disease.

    • New-to-plan members are those with a coverage effective date of 90 days or less.
    • The diagnosis-specific pathway requires the applicable diagnosis and satisfaction of one qualifying treatment pathway.

    Clinical Background

    Vedolizumab is an integrin receptor antagonist. The subcutaneous formulation, Entyvio SC, is indicated for adults with moderately to severely active ulcerative colitis or moderately to severely active Crohn’s disease. The policy includes access to Entyvio SC for maintenance after intravenous induction or continuation of therapy following at least 2 doses of Entyvio IV.

    Drug Definition

    Entyvio (vedolizumab) subcutaneous
    Drug classIntegrin receptor antagonist
    Ulcerative colitis indicationModerately to severely active ulcerative colitis in adults
    Crohn’s disease indicationModerately to severely active Crohn’s disease in adults

    Initial Entyvio SC Authorization

    Entyvio SC initial authorization

    Authorization may be granted for the applicable diagnosis when all diagnosis-specific criteria are met and one treatment pathway is satisfied.

    Diagnosis-specific authorization pathway

    • Ulcerative colitis pathway

      • Qualifying treatment pathway

        • Entyvio subcutaneous formulation will be used as maintenance following at least two doses of Entyvio IV induction.At least 2 Entyvio IV doses
        • Member started therapy with at least two doses of Entyvio IV and is continuing treatment with the subcutaneous formulation.At least 2 Entyvio IV doses

    Entyvio SC Continuation

    Entyvio SC continuation

    Requests for reauthorization will be approved when all of the following criteria are met:

    Clinical improvement: Submission of medical records, such as chart notes, documenting improvement in the member's condition, evidenced by low disease activity or improvement in signs and symptoms.Low disease activity or improvement in signs and symptoms

    Required Alternative Therapies

    Alternative therapiesRequired action
    Any two of the following: Adalimumab-aaty, adalimumab-adaz, or Hadlima; Omvoh; Rinvoq; Simponi; Skyrizi; Selarsdi, Steqeyma, or Yesintek; Tremfya; VelsipityTrial and failure, contraindication, or intolerance of two alternatives
    Alternative therapiesRequired action
    Any two of the following: Cimzia; adalimumab-aaty, adalimumab-adaz, or Hadlima; Omvoh; Rinvoq; Skyrizi; Selarsdi, Steqeyma, or Yesintek; TremfyaTrial and failure, contraindication, or intolerance of two alternatives

    Quantity Limits

    Entyvio SC pen
    Quantity limit2 pens per 28 days
    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyEntyvio SC (vedolizumab) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJanuary 1, 2027
    Last ReviewOct 14, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of the applicable diagnosis and either at least two Entyvio IV doses or trial, failure, contraindication, or intolerance to two listed alternatives.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and Authorization RequirementsClinical BackgroundDrug DefinitionInitial Entyvio SC AuthorizationEntyvio SC ContinuationRequired Alternative TherapiesQuantity Limits
    Velsipity
    Cimzia
  1. Adalimumab-aaty, adalimumab-adaz, or Hadlima
  2. Omvoh
  3. Rinvoq
  4. Skyrizi
  5. Selarsdi, Steqeyma, or Yesintek
  6. Tremfya
  7. Step Therapy

    Ulcerative Colitis Alternative-Therapy Pathway

    For moderately to severely active ulcerative colitis, the member must have the diagnosis and satisfy one of the applicable Entyvio or alternative-therapy pathways.

    • Entyvio SC will be used as maintenance following at least two doses of Entyvio IV induction; or the member started therapy with at least two doses of Entyvio IV and is continuing Entyvio SC.
    • Alternatively, the member must have trialed and failed, or have a contraindication or intolerance to, two of the following: adalimumab-aaty, adalimumab-adaz, or Hadlima; Omvoh; Rinvoq; Simponi; Skyrizi; Selarsdi, Steqeyma, or Yesintek; Tremfya; or Velsipity.
    Step Therapy

    Crohn's Disease Alternative-Therapy Pathway

    For moderately to severely active Crohn's disease, the member must have the diagnosis and satisfy one of the applicable Entyvio or alternative-therapy pathways.

    • Entyvio SC will be used as maintenance following at least two doses of Entyvio IV induction; or the member started therapy with at least two doses of Entyvio IV and is continuing Entyvio SC.
    • Alternatively, the member must have trialed and failed, or have a contraindication or intolerance to, two of the following: Cimzia; adalimumab-aaty, adalimumab-adaz, or Hadlima; Omvoh; Rinvoq; Skyrizi; Selarsdi, Steqeyma, or Yesintek; or Tremfya.
    Documentation Required

    New-to-Plan Current-Treatment Documentation

    For a member new to the plan, submit medical records documenting that the member is currently receiving the requested drug.

    • Applies when the member's coverage effective date is 90 days or less.
    • Do not use samples or manufacturer patient assistance program participation as evidence of current treatment.
    Documentation Required

    Reauthorization Response Documentation

    Reauthorization requests require chart-note or comparable medical-record documentation showing that the member's condition has improved.

    • Document low disease activity or improvement in the signs and symptoms of the condition.
    • Initial approvals and reauthorizations are granted for 24 months.
    Denial Risk

    Diagnosis or Required Pathway Not Met

    Authorization may be denied when the required diagnosis is not documented or when the member does not meet an applicable treatment pathway.

    • The applicable pathway must include Entyvio IV induction and continuation or the required trial, contraindication, or intolerance of the specified alternatives.
    Denial Risk

    Insufficient Response Documentation

    Reauthorization may be denied when the submitted records do not document clinical improvement or an appropriate treatment response.

    • Submit chart notes documenting low disease activity or improvement in signs and symptoms.
    Billing Rule

    Quantity Limit Exceeded

    Claims exceeding the Entyvio SC pen quantity limit may be denied.

    • Entyvio SC pen: maximum 2 pens per 28 days.
    Member has trialed and failed, has a contraindication to, or is intolerant of two listed ulcerative colitis alternatives.2 alternatives

    The applicable alternatives are adalimumab-aaty, adalimumab-adaz, Hadlima, Omvoh, Rinvoq, Simponi, Skyrizi, Selarsdi, Steqeyma, Yesintek, Tremfya, and Velsipity.

  8. Crohn's disease pathway

    • Qualifying treatment pathway

      • Entyvio subcutaneous formulation will be used as maintenance following at least two doses of Entyvio IV induction.At least 2 Entyvio IV doses
      • Member started therapy with at least two doses of Entyvio IV and is continuing treatment with the subcutaneous formulation.At least 2 Entyvio IV doses
      • Member has trialed and failed, has a contraindication to, or is intolerant of two listed Crohn's disease alternatives.2 alternatives

        The applicable alternatives are Cimzia, adalimumab-aaty, adalimumab-adaz, Hadlima, Omvoh, Rinvoq, Skyrizi, Selarsdi, Steqeyma, Yesintek, and Tremfya.